Alterity Therapeutics Reports Change of Director's Interest Notice

Alterity Therapeutics Limited filed a Form 6-K with the SEC on June 17, 2026, reporting changes in director interests. The filing specifically includes two 'Change of Director’s Interest' notices submitted as Exhibit 99.1. These notices typically detail changes in the shareholding or options held by members of the company's Board of Directors. The document was signed by Julian Babarczy, the Chairman of Alterity Therapeutics. This disclosure is a routine regulatory requirement for foreign private issuers listed on U.S. exchanges to maintain transparency regarding the financial interests of their leadership. No other material updates regarding clinical trials, financial results, or corporate strategy were provided in this specific filing. The information is incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3.